Evidence map›Paper›PMID 41714090›Full record

ArticleBMJ open respiratory research2026

Elevated serum peroxiredoxin 1 is a biomarker of multiorgan failure in ARDS.

Guoliang Jiang, Yan Zhang, Hanwei Huang, Pan Yu, Lingzhi Long, Xiangyu Zhang, Tingting Yao, Xiaoyun Cheng, Yifan Liu, Lijun Zou and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Guoliang JiangDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yan ZhangHunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, Hunan, China.
Hanwei HuangHunan Key Laboratory of Organ Fibrosis, Central South University, Changsha, Hunan, China.
Pan YuDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lingzhi LongDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiangyu ZhangDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Tingting YaoDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Xiaoyun ChengDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.ORCID http://orcid.org/0000-0002-0975-5122
Yifan LiuDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Lijun ZouDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Yijun HeDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Mao JiangDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China.
Jie MengDepartment of Respiratory and Critical Care Medicine, Third Xiangya Hospital of Central South University, Changsha, Hunan, China mengjie@csu.edu.cn.ORCID http://orcid.org/0000-0002-4402-1589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome with high morbidity and mortality. Despite advances in understanding its pathophysiology, definitive biomarkers for ARDS disease stratification and management remain lacking. This study evaluated the utility of circulating PRDX1 in predicting 28-day mortality in ARDS patients.

methodsA retrospective cohort study was conducted at Third Xiangya Hospital, enrolling 90 ARDS patients. Serum PRDX1 levels and clinical data were collected and compared with those from healthy volunteers and non-ARDS pneumonia patients to examine its alterations in ARDS patients; multivariate logistic regression and receiver operating characteristic (ROC) curve analyses were then employed to assess the prognostic value of circulating PRDX1 for 28-day mortality. An independent validation cohort of 20 ARDS patients was recruited from Xiangya Hospital intensive care units. Additionally, serum Prdx1 dynamics were assessed in LPS-induced acute lung injury (ALI) and sepsis-associated ALI murine models.

resultsSerum PRDX1 levels were significantly elevated in a cohort of 90 ARDS patients, particularly among those with multiorgan injury. Multivariate analysis identified PRDX1 and age as independent risk factors for 28-day mortality. ROC curves revealed PRDX1's prognostic utility (area under the curve, AUC=0.776, p<0.0001), which was comparable to the APACHE II score (AUC=0.778, p<0.0001). These findings were validated in the 20-patient cohort. Animal experiments confirmed that serum PRDX1 positively correlated with lung injury severity and exhibited earlier elevation and higher abundance in multiorgan injury contexts.

conclusionsSerum PRDX1 was significantly elevated in ARDS patients, particularly in those with multiorgan injury, and demonstrated potential as a prognostic biomarker, showing correlation with 28-day mortality. Its integration into the ARDS management framework holds significant potential for improving clinical outcomes.

Indexed as

Multiple Organ FailurePeroxiredoxinsRespiratory Distress SyndromeAcute Lung InjuryAdultAgedAnimalsBiomarkersFemaleHumansMaleMiceMiddle AgedPrognosisRetrospective StudiesRisk FactorsBiomarkersPeroxiredoxinsPRDX1 protein, humanARDS

Identifiers

PMID41714090
PMCPMC12927329

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.